A huge thank you to you and all our 2014 Jett Foundation supporters. We had a good year with progress to end Duchenne. I'm proud of our work for safe and effective therapies for those who need them, and our efforts to support the Duchenne community with our programs. I'm grateful for all the help and generosity that made it happen. Thank you.
This year is going to bring more great progress. We will continue our dedication to get therapies for those who need them as quickly as possible. Please read below about the Race to Yes and Sarepta's most recent data.
We are also gearing up for a great year with amazing programs and support for the entire Duchenne community.
And of course, it's football time - so here's one of my favorite photos from our Jett Foundation day at Training Camp!
Why the unreasonable delays and barriers to approval for eteplirsen?
This week, Sarepta Therapeutics released 168 week data from its ongoing eteplirsen study. This new data strongly confirms the safety and efficacy of eteplirsen and once again calls into question the unreasonable delays and barriers to approval raised by the Division of Neurology Products at the FDA. Read more and join with us in the Race to Yes and get this much needed drug to all with Duchenne as soon as possible.
Our Goal: Eliminate the challenges of Duchenne through research and services.